皮下投与（ドラッグデリバリー）の世界市場及びパイプライン分析...市場調査レポートについてご紹介

1. Introduction to Subcutaneous Drug Delivery

2. Mechanism of Subcutaneous Drug Delivery

3. Subcutaneous Drug Delivery Market Overview
3.1 Current Market Scenario
3.2 Subcutaneous Drug Delivery Pipeline Overview

4. Subcutaneous Drug Delivery Market Dynamics
4.1 Favorable market Parameters
4.2 Clinical & Commercialization Challenges

5. Devices for Subcutaneous Drug Delivery
5.1 Syringe Based Subcutaneous Drug Delivery
5.2 Subcutaneous Implants
5.3 Pen Systems for Subcutaneous Drug Delivery
5.4 Auto Injectors
5.5 Pump Based Drug Delivery Systems

6. Subcutaneous Drug Delivery Market Future Prospects

7. Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Phase: Preregistration
7.11 Phase: Registered

8. Marketed Subcutaneous Drug Clinical Insight

9. Discontinued & Suspended Subcutaneous Drugs in Clinical Trials
9.1 No Development Reported
9.2 Discontinued
9.3 Preregistration-Submission Withdrawal
9.4 Market Withdrawal
9.5 Suspended

10. Competitive Landscape
10.1 Boehringer Ingelheim
10.2 Eli Lily
10.3 Galaxo
10.4 HMD pharmaceuticals
10.5 Merck
10.6 Novartis
10.7 Novo Nordisk
10.8 Pfizer
10.9 Sanofi
10.10 Teva Pharmaceutical
10.11 Zogenix

Figure 1-1: Functions of Skin Tissue
Figure 1-2: Different Functions of Skin Layers
Figure 1-3: Benefits of Subcutaneous Drug Delivery Site
Figure 1-4: Sites for Subcutaneous Drug Administration
Figure 1-5: Limitations of Subcutaneous Drug Delivery Site
Figure 2-1: External Factors to Increase Absorbability of Subcutaneous Drugs
Figure 2-2: Mechanism of Exogenous Insulin Administration at Subcutaneous Site
Figure 3-1: Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-2: Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-3: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-4: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-5: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-6: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-7: Suspended Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-8: Suspended Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 4-1: Drivers for Intramuscular Drug Delivery Market
Figure 4-2: Clinical & Commercialization Challenges
Figure 5-1: Classification of Subcutaneous Drug Delivery Devices
Figure 5-2: Syringe Based Subcutaneous Drug Delivery
Figure 5-3: Implant Based Subcutaneous Drug Delivery
Figure 5-4: Description of Pen Systems for Subcutaneous Drug Delivery
Figure 5-5: Benefits & Drawbacks Pen Systems for Subcutaneous Drug Delivery
Figure 5-6: Auto Injectors for Subcutaneous Drug Delivery
Figure 5-7: Different Part of Pump Based Subcutaneous Drug Delivery Device

Table 5-1: Comparative Analysis of Different Subcutaneous Drug Delivery Systems